A First Glance at This Hedge Fund Firm’s Strategic Q2 Moves in Biotech Sector
What’s Gilead Sciences Next M&A Move? Kite Pharma!
Kite Pharma Inc (NASDAQ:KITE) announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a …
On January 5th, biopharmaceutical company Amgen Inc. (NASDAQ: AMGN) announced plans to collaborate with Kite Pharma (NASDAQ: KITE) on cancer treatments.
